Barely Significant
← all excerpts

<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.

Oncoimmunology · 2023 · PMC10588513 · PMID 37868689

Europe PMCDOI
2
hedged sentences
0.0790
closest p · 1.6× alpha
0.1100
boldest claim

The sentences

showed a trendP = 0.079so close (0.05 < p ≤ 0.1)
In univariable Cox, mPD-L1 methylation as a continuous variable showed a trend toward improved PFS and OS (PFS: HR = 1.01 [95%-CI 1.00–1.03], P = 0.079; OS; HR = 1.01 [95%-CI 1.00–1.03], P = 0.072).

also in 53,322 other papers

did not reach statistical significancep = 0.11not close (p > 0.1)
12–18 In melanoma, hypomethylation of the PD-L1 promoter appeared to be associated with an improved response to ICB, although the results did not reach statistical significance ( p = 0.11) which was probably attributed to a small cohort size of N = 43. 16 However, it has already been proven that the methylation status of immune checkpoint genes such as CTLA4 can predict response to ICB. 19–21 The aim of our present study was therefore to evaluate the predictive potential of PD-L1 promoter methylation status ( mPD-L1 ) in ICB-treated mUC as valid predictive and prognostic biomarkers are lacking.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.